ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

A number of other equities research analysts have also recently commented on PRQR. BidaskClub upgraded Misonix from a buy rating to a strong-buy rating in a research report on Wednesday, July 3rd. ValuEngine cut Welbilt from a hold rating to a sell rating in a report on Wednesday, June 12th. Finally, Chardan Capital lifted their price objective on Krystal Biotech from $50.00 to $57.50 and gave the stock a buy rating in a report on Tuesday, March 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $28.67.

NASDAQ:PRQR opened at $9.07 on Wednesday. ProQR Therapeutics has a 52 week low of $6.40 and a 52 week high of $24.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.08 and a current ratio of 10.08. The company’s 50-day simple moving average is $10.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.05). As a group, analysts expect that ProQR Therapeutics will post -1.65 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of PRQR. BlackRock Inc. acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $11,064,000. Hsbc Holdings PLC purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $7,890,000. Nikko Asset Management Americas Inc. purchased a new position in ProQR Therapeutics in the 1st quarter worth approximately $4,016,000. FMR LLC lifted its stake in ProQR Therapeutics by 27.8% in the 4th quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock worth $17,064,000 after purchasing an additional 235,053 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $1,428,000. Institutional investors own 61.75% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.